I am hoping with Mylan not having first right of refusal on RT002 partnership in NA markets, big pharma will step in to partner; something similar in scale like ABBV did with ENTA
Revance has lot of IP protections on their toxin and good pipeline; so with expanding Botox market, big pharma looking for steady and predictable revenue growth should ink the deal asap but on RVNC terms.
Hoping Dan doesn’t have to send another excuse letter to investors if the deal is sub-par :(
Market Data 
Markets 
AI
